Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 11;13:609–616. doi: 10.2147/IMCRJ.S267867

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Jindahra et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Diagram showing individual trajectories of the CD4 cell count over time in the non-infectious (immune-mediated) ON group. Each color line and the corresponding arrow color represents each patient. Small arrows represent acute ON attacks. Black dots represent antiretroviral initiation. Black rings represent steroid treatments. Three patients (blue, light blue, and purple lines) successfully achieved HIV infection control. They developed acute ON while their CD4 cell counts were rising, and HIV viral load became undetectable. A female patient (black line), who did not receive ART, developed NMOSD-ON while her CD4 cell counts were 371 cells/µL. All the patients in this group did not have opportunistic infections and were responsive to corticosteroid treatments.